Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2009 Results
Date:8/10/2009

nificant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's products to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements for its products; a lack of acceptance of Vanda's products in the marketplace, or a failure to become or remain profitable; Vanda's expectations regarding trends with respect to its costs and expenses; Vanda's inability to obtain the capital necessary to fund its commercial and research and development activities; Vanda's failure to identify or obtain rights to new products; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2009 (File No. 001-34186). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf a
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports First Quarter 2009 Results
9. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
10. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Los Angeles (PRWEB) August 22, 2014 ... for age-defying products, is in the spotlight again. ... night cream and its NeriumFirmTM Body Contouring Cream ... presented by Backstage Creations during the 66th Primetime ... the patented NAE-8® extract, third-party clinical trials show ...
(Date:8/21/2014)... 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® ... and XIAPEX ® in the EU, today ... double-blind Phase 2a study of CCH for the ... The results showed that all three doses of ...
(Date:8/21/2014)... international research team including DESY scientists has observed tiny ... team reports in the journal Science that ... inside the nanodroplets. It is the first time that ... larger samples of what is known as superfluid helium, ... our best expectations," says Andrey Vilesov of the University ...
(Date:8/21/2014)... IA (PRWEB) August 21, 2014 His ... LIBERTY Opening , The Court of His Majesty Willem-Alexander, ... will attend the Grand Opening of POET-DSM Advanced Biofuels’ ... Wednesday, Sept. 3. , The King will take part ... opening activity, scheduled for 11 a.m.-12:20 p.m. and tour ...
Breaking Biology Technology:Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3
... 19 MAKO Surgical,Corp. today announced that it has filed ... Exchange Commission relating to a proposed,initial public offering of its ... sold by MAKO Surgical Corp. The,number of shares to be ... been determined. The Company intends to apply to have its ...
... AMSTERDAM, September 19 - IDF Launches ... IDF today issued the new global guideline ... glucose.(1) The guideline emphasizes,that people with diabetes should ... in order to optimize diabetes control and reduce ...
... BASEL, Switzerland, September 19 ,Arpida Ltd (SWX: ARPN) ... summary session of new antimicrobial agents at the ... (ICAAC) in,Chicago. ICAAC is a major scientific conference ... the world gather to discuss the,latest developments in ...
Cached Biology Technology:MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock 2The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes 2The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes 3Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 3
(Date:8/21/2014)... of American singles found that during sex with ... rates. On average, men experience orgasm 85.1 percent ... little difference. For women, however, orgasm occurrence is ... percent of the time during sex with a ... women,s sexual orientation, with lesbian women experiencing orgasm ...
(Date:8/21/2014)... a previously unknown process for harvesting energy and producing ... Penn State University scientist has discovered. The discovery lays ... growth, harvesting energy from the Sun, and understanding dense ... other lakes worldwide. A paper describing the discovery will ... of the journal Science on 21 August ...
(Date:8/21/2014)... ubiquitous skin fungus linked to dandruff, eczema and other ... to even further global reachesincluding Hawaiian coral reefs and ... vents. , A review in the scientific journal ... of the fungi of the genus Malassezia ... sequencing datasets from around the world. , University of ...
Breaking Biology News(10 mins):Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2
... South Korea, Jan. 8 Pixelplus Co.,Ltd. ... company in Korea that designs,develops, and markets ... today announced that it unveiled the "PM1002", ... image recognition,applications., The PM1002 integrates a ...
... 8, 2008) Adolescent girls who frequently eat meals ... pills, laxatives, or other extreme measures to control their ... Dianne Neumark-Sztainer, Ph.D., M.P.H., R.D., lead investigator of Project ... Minnesota School of Public Health. Neumark-Sztainer and Project ...
... Philadelphia, PA, January 8, 2008 Schizophrenia is a ... increased risk. Available antipsychotic medications treat some of ... only a subset of patients. Unfortunately, it is ... in any given individual with schizophrenia. John H. ...
Cached Biology News:Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition 2Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition 3U of M research finds disordered eating less common among teen girls who regularly eat family meals 2Genetic variant predicts antipsychotic response for schizophrenia patients by ethnicity 2
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... Mucin 3 (MUC3) is a glycoprotein. ... a lesser extent in breast, lung and ... shows no cross-reaction with MUC1 and MUC2. ... human MUC3 Immunogen: MUC3 tandem ...
... CDX2, a member of the caudal-related ... that regulates both proliferation and differentiation in ... role in triggering cells towards the phenotype ... in the maintenance of the phenotype. Clone ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Biology Products: